scholarly journals A study of analysis of LA remodelling and pathophysiologic determinants of LA volume in patients with LV dysfunction in patients with dilated cardiomyopathy

2020 ◽  
Vol 15 (2) ◽  
pp. 51-55
Author(s):  
Reddi Basha Saheb Shaik ◽  
Keyword(s):  
Dilated Cardiomyopathy ◽  
Lv Dysfunction

scholarly journals Bridge to recovery with Berlin Heart EXCOR in children <10 kg with dilated cardiomyopathy: a histological analysis

2020 ◽  
Vol 58 (2) ◽  
pp. 253-260 ◽  
Author(s):  
Yuji Tominaga ◽  
Takayoshi Ueno ◽  
Takashi Kido ◽  
Tomomitsu Kanaya ◽  
Jun Narita ◽  
...  
Keyword(s):  
Dilated Cardiomyopathy ◽  
Left Ventricular ◽  
Lv Function ◽  
Vascular Density ◽  
Bridge To Recovery ◽  
High Power Field ◽  
Lv Dysfunction ◽  
Paediatric Patients ◽  
Berlin Heart ◽  
Recovery Group

Abstract OBJECTIVES This study aimed to identify the histological characteristics associated with bridge to recovery using Berlin Heart EXCOR® (BHE) in paediatric patients &lt;10 kg with dilated cardiomyopathy. METHODS Of the 10 consecutive patients &lt;10 kg with dilated cardiomyopathy who underwent BHE implantation between 2013 and 2018, 4 patients showed improvement in left ventricular (LV) function, resulting in successful BHE explantation (recovery group). The remaining 6 patients showed persistent LV dysfunction and underwent heart transplantation (non-recovery group). The following variables were compared between the 2 groups: (i) histological findings in LV myocardium obtained at BHE implantation and (ii) LV function after BHE implantation assessed with echocardiography and cardiac catheterization. RESULTS The degree of myocardial fibrosis was significantly lower, and the capillary vascular density was significantly higher in the recovery group than in the non-recovery group [16% (standard deviation 5.9%) vs 28% (5.9%), P = 0.021, and 65 (11) vs 43 (18) units/high-power field, P = 0.037, respectively]. The changes during 3 months after BHE implantation in LV diastolic dimension (z-score) and ejection fraction were significantly greater in the recovery group than in the non-recovery group [−9.6 (3.5) vs −3.6 (4.5), P = 0.045, and 36% (13%) vs 13% (13%), P = 0.032, respectively]. CONCLUSIONS In paediatric patients &lt;10 kg with dilated cardiomyopathy, bridge to recovery with BHE implantation was achieved in patients with less injured LV myocardial histology at BHE implantation.

scholarly journals Hot balloon ablation of persistent atrial fibrillation with a dilated left atrium in a case of dilated cardiomyopathy

2017 ◽  
Vol 4 (2) ◽  
pp. 28
Author(s):  
Ayako Okada ◽  
Morio Shoda ◽  
Takahiro Takeuchi ◽  
Ken Kato ◽  
Wataru Shoin ◽  
...  
Keyword(s):  
Heart Failure ◽  
Atrial Fibrillation ◽  
Congestive Heart Failure ◽  
Dilated Cardiomyopathy ◽  
Left Atrium ◽  
Persistent Atrial Fibrillation ◽  
Left Ventricular Ejection ◽  
Lv Dysfunction ◽  
Intravenous Drip ◽  
Balloon Ablation

A 70-year-old man who developed dilated cardiomyopathy with persistent atrial fibrillation (PSAF) was admitted to our hospital. He was already drug-resistant. The left atrium (LA) was severely enlarged. The left ventricular ejection fraction (LVEF) was 39%, and contraction was severely reduced. For AF ablation, catheter ablation (CA) was used for mild to moderate LV dysfunction without severe left atrial dilatation. In severe LV dysfunction, excessive intravenous drip volume may precipitate congestive heart failure. On the other hand, shorter isolation time has been reported with balloon ablation as compared to CA. Therefore, the intravenous drip volume is small. We planned to use the balloon technique for a patient with LA dilatation and severe LV dysfunction despite another hospital not having done so. After the procedure, the pulmonary veins were successfully isolated, and congestive heart failure recovered after sinus rhythm termination. There was no recurrence of AF after the procedure. Hot balloon ablation can be effective for PSAF with severe heart failure.

scholarly journals Four-dimensional blood flow-specific markers of LV dysfunction in dilated cardiomyopathy

2012 ◽  
Vol 14 (5) ◽  
pp. 417-424 ◽  
Author(s):  
Jonatan Eriksson ◽  
Ann F. Bolger ◽  
Tino Ebbers ◽  
Carl-Johan Carlhäll
Keyword(s):  
Blood Flow ◽  
Dilated Cardiomyopathy ◽  
Lv Dysfunction

scholarly journals Thyrotoxic dilated cardiomyopathy: personal experience and case collection from the literature

2020 ◽  
Vol 2020 ◽  
Author(s):  
Giuseppina Molinaro ◽  
Renato De Vecchis ◽  
Elio Badolati ◽  
Raffaele Giannattasio
Keyword(s):  
Cardiogenic Shock ◽  
Dilated Cardiomyopathy ◽  
Beta Blocker ◽  
Case Reports ◽  
List Type ◽  
Lv Dysfunction ◽  
Long Latency ◽  
Case Collection ◽  
Learning Points ◽  
Mechanical Assistance

Summary The authors examine several reports of the literature concerning thyrotoxic dilated cardiomyopathy. In particular, it is pointed out that this clinical manifestation of hyperthyroidism is rare in readily diagnosed and properly treated hyperthyroidism. Case reports are analyzed comparatively. A case deriving from the direct experience of the authors is also presented. Learning points: Dilated cardiomyopathy has been reported as the initial presentation of hyperthyroidism in only 6% of patients although <1% developed severe LV dysfunction. Clinical picture of thyrotoxic dilated cardiomyopathy can degenerate into an overt cardiogenic shock sometimes requiring the use of devices for mechanical assistance to the circulation, or extracorporeal membrane oxygenation. For thyrotoxic dilated cardiomyopathy, evidence-based pharmacologic measures valid for heart failure should always be supplemented by the administration of specific thyroid therapies such as thionamides (methimazole, carbimazole or propylthiouracil), whose relatively long latency of action should be supported by the i.v. administration of small doses of beta-blocker. In cases of cardiogenic shock, the administration of beta-blocker should be carried out only after the restoration of satisfactory blood pressure levels- with the prudent use of synthetic catecholamines, if necessary.

scholarly journals Can Serum Tenascin-C Be Used as a Marker of Inflammation in Patients with Dilated Cardiomyopathy?

2013 ◽  
Vol 2013 ◽  
pp. 1-6 ◽  
Author(s):  
Alyaa A. Kotby ◽  
Manal M. Abdel Aziz ◽  
Waleed M. El Guindy ◽  
Amira N. Moneer
Keyword(s):  
Dilated Cardiomyopathy ◽  
Acute Onset ◽  
Peak Strain ◽  
Tenascin C ◽  
Lv Dysfunction ◽  
Group I ◽  
Echocardiographic Evaluation ◽  
Significant Difference ◽  
Group Ii ◽  
Active Inflammation

Background. Tenascin-C (TN-C) is an extracellular matrix glycoprotein that appears at sites of inflammation in cardiac pathologies.Aim of the Work. To evaluate the role of TN-C as a marker for active inflammation in children with dilated cardiomyopathy (DCM).Subjects and Methods. 24 consecutive patients with primary nonfamilial DCM aged 6–72 months (mean45.19±11.03) were divided into group I, twelve patients with acute onset DCM (<6 months duration), and group II, twelve patients with chronic DCM (>6 months duration), and compared to 20 healthy age- and sex-matched controls. Investigations included estimation of serum TN-C and echocardiographic evaluation using M-mode and 2D speckle tracking echocardiography (STE).Results. Serum TN-C showed a higher significant statistical elevation among patients than controls (P<0.001) and in group I than group II (P<0.001). EF was significantly decreased, and LVEDD and EDV increased in patients than controls and in GI than GII. STE showed a statistically significant difference in global peak strain longitudinal (GPSL) average in patients than controls (P<0.05) and between GI and GII (P<0.001). STE wall motion scoring showed normokinesia (33.5%), hypokinesia (8.33%), and akinesia (50%) in GI and hypokinesia (100%) in GII. There was a statistically significant positive correlation between serum TN-C and GPSL average.Conclusions. Increased serum TN-C can be used as a marker of inflammation in DCM and is associated with the severity of heart failure and LV dysfunction as detected by STE.

scholarly journals Reversible dilated cardiomyopathy: into the thaumaturgy of the heart - Part 2

2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Giovanni Quarta ◽  
Raffaele Coppini ◽  
Pier Lambiase ◽  
Pablo Garcia-Pavia ◽  
Alice Calabrese ◽  
...  
Keyword(s):  
Dilated Cardiomyopathy ◽  
Genetic Background ◽  
Morphological Changes ◽  
Systolic Dysfunction ◽  
Left Ventricular ◽  
Peripartum Cardiomyopathy ◽  
Pathogenic Agent ◽  
Lv Dysfunction ◽  
Muscle Disorder ◽  
Novel Therapeutic

Dilated cardiomyopathy (DCM) is a genetic or acquired heart muscle disorder characterized by dilation and impaired contraction of one or both ventricles. In the acquired forms of the disease, if the pathogenic agent is persistent, undiagnosed or untreated, permanent ultrastructural and morphological changes may lead to irreversible dysfunction. Conversely, when DCM is promptly recognized and treated, the heart may show an extraordinary ability to recover from left ventricular (LV) systolic dysfunction. While much research in heart failure has focused on morbidity and mortality associated with persistent LV systolic dysfunction, relatively little attention has been devoted to this remarkable potential for recovery. In this two-part review we will focus on the most common types of reversible DCM. The second part will deal with chemotherapy-induced cardiomyopathy, alcohol- related cardiomyopathy, myocarditis and peripartum cardiomyopathy. Although diverse in etiopathogenesis, genetic background, therapeutic options and outcome, the forms of DCM characterized by reversible LV dysfunction share similar challenges in diagnosis and clinical management. The identification of pathways to recovery may show the way for novel therapeutic targets ultimately benefitting all cardiac patients.

scholarly journals Reversible dilated cardiomyopathy: into the thaumaturgy of the heart - Part 1

2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Giovanni Quarta ◽  
Raffale Coppini ◽  
Pier Lambiase ◽  
Pablo Garcia-Pavia ◽  
Alice Calabrese ◽  
...  
Keyword(s):  
Dilated Cardiomyopathy ◽  
Morphological Changes ◽  
Systolic Dysfunction ◽  
Left Ventricular ◽  
Ventricular Assist ◽  
Device Implantation ◽  
Lv Dysfunction ◽  
Left Ventricular Assist ◽  
Muscle Disorder ◽  
Tako Tsubo Cardiomyopathy

Dilated cardiomyopathy (DCM) is a genetic or acquired heart muscle disorder characterized by dilation and impaired contraction of one or both ventricles. In the acquired forms of the disease, if the pathogenic agent is persistent, undiagnosed or untreated, permanent ultrastructural and morphological changes may lead to irreversible dysfunction. Conversely, when DCM is promptly recognized and treated, the heart may show an extraordinary ability to recover from left ventricular (LV) systolic dysfunction. While much research in heart failure has focused on morbidity and mortality associated with persistent LV systolic dysfunction, relatively little attention has been devoted to this remarkable potential for recovery. In this two-part review we will focus on the most common types of reversible DCM. The first part will deal with Tako-Tsubo cardiomyopathy, tachycardiainduced cardiomyopathy, metabolic DCM and recovery after Left ventricular assist device implantation. Although diverse in etiopathogenesis, genetic background, therapeutic options and outcome, the forms of DCM characterized by reversible LV dysfunction share similar challenges in diagnosis and clinical management. The identification of pathways to recovery may show the way for novel therapeutic targets ultimately benefitting all cardiac patients.

scholarly journals Early- and late anthracycline-induced cardiac dysfunction: echocardiographic characterization and response to heart failure therapy

2020 ◽  
Vol 6 (1) ◽  
Author(s):  
Janine A. M. Kamphuis ◽  
Marijke Linschoten ◽  
Maarten J. Cramer ◽  
Pieter A. Doevendans ◽  
Folkert W. Asselbergs ◽  
...  
Keyword(s):  
Heart Failure ◽  
Cardiac Function ◽  
Dilated Cardiomyopathy ◽  
Outpatient Clinic ◽  
Cardiac Dysfunction ◽  
Poor Response ◽  
Partial Recovery ◽  
Lv Dysfunction ◽  
Anticancer Treatment ◽  
The Impact

Abstract Background Anthracycline-induced cardiac dysfunction (ACD) is a notorious side effect of anticancer treatment. It has been described as a phenomenon of a continuous progressive decline of cardiac function, eventually leading to dilated cardiomyopathy (DCM). This progressive nature suggests that patients with a delayed ACD diagnosis have greater compromise of cardiac function and more adverse remodeling, with a poor response to heart failure (HF) treatment. This study aimed to delineate the impact of a delayed ACD diagnosis on echocardiographic characteristics and response to HF treatment. Methods and results From the population of our cardio-oncology outpatient clinic, 92 ACD patients were included in this study (age 51.6 ± 16.2 years, median cumulative anthracycline dose 329 [200–329] mg/m2), and a median follow-up of 25.0 [9.6–37.2] months after ACD diagnosis. Median time to ACD diagnosis for patients diagnosed early (< 1 year) and late (> 1 year) was 4.0 vs. 47.7 months respectively. There were no echocardiographic differences between patients diagnosed early vs. late (LVEF 43.6 ± 4.9% vs. 43.0 ± 6.2% and iEDV 63.6 vs. 62.9 mL/m2). Eighty-three percent of patients presented with mild LV dysfunction and in 79% the LV was not dilated. Patients diagnosed early were more likely to have (partial) recovery of cardiac function upon HF treatment initiation (p = 0.015). Conclusions In the setting of a cardio-oncology outpatient clinic, patients with ACD presented with a hypokinetic non-dilated cardiomyopathy, rather than typical DCM. Timing of ACD diagnosis did not impact HF disease severity. However, in patients receiving an early diagnosis, cardiac function was more likely to recover upon HF treatment.

Sign in / Sign up

Export Citation Format

Share Document